Search
by Jasmine Pennic / hitconsultant.net
- 2 min
Patients Are Increasingly Using Digital Health to Supplement Doctor Visits
61% of patients reported that they were likely to ask for a specific prescription medication by name, implying research prior to appointments, with Millennials the most likely generational group to ask for a specific prescription medication by name (69%). Consumers are increasingly leveraging online resources to both prepare for appointments and validate physician recommendations – moving beyond diagnosis to become more active in the treatment decision, according to new findi
© 2015 Amgen Inc. All Rights Reserved.
- 2 min
The Safety of Biosimilars and the importance of the INN to track and trace the use of a medicine gi
Tracking and tracing the use of all biologics, including biosimilars, enhances patient safety. Where there are multiple companies developing a biosimilar of the same reference molecule, distinct non-proprietary names for each of those biosimilars is fundamental to traceability. Physicians need complete and accurate data on adverse events linked to a specific treatment to facilitate optimal prescribing for each of their specific patients every time. An infrastructure that supp
Edward Carstairs of Gill Jennings & Every LLP
- 4 min
Name that drug
The role of the European Medicines Agency (EMA) as a regulator is to protect and promote public and animal health by evaluating and supervising medication for both human and veterinary use. The EMA was created to harmonise the working practices of the various EU member state territories. It also reduces the costs for those requiring approval throughout the EU. It is only after authorisation has been granted that a company can market a product. However, while regulatory approv
By Paul Norman / Pharmaceutical Executive Europe
- 7 min
What's the Prescription for a Perfect Name?
With Viagra and Prozac rivaling McDonald's and Coca-Cola among today's most frequently used brand names, it's no surprise that pharmaceutical manufacturers are taking the whole issue of product branding very seriously. Gone are the days when consumers were happy to trust their pharmacist's advice when it came to cough mixture or heartburn remedy. Now, they frequently know exactly what they want and are even sufficiently well informed to ask their GPs to prescribe certain bran
By Pharmaceutical Executive Editors
- 3 min
EGA Becomes Medicines for Europe
The European Generic and Biosimilar Medicines Association (EGA) has changed its name to Medicines for Europe. In a press release issued today, Medicines for Europe President Jacek Glinka explained that the repositioning "reflects our industries’ purpose and strategic objectives ... [W]e have been through an incredible journey responding to the changes that have taken place in the pharmaceutical industry and European healthcare environment. I invite stakeholders and policy-mak
by Joseph Keenan / FiercePharma
- 2 min
Hanmi's $200M China plant likely to make branded drugs versus generics
South Korean drug manufacturer Hanmi is building a $200 million manufacturing plant and R&D center in China, though it won't, apparently, be producing generic drugs at the facility. The company announced earlier this year it would build the plant on a 200,000-square-meter swath of land near Yantai in an economic development zone in the eastern province of Shandong. The facility will be the production site for chemosynthetic and biological drugs as well as various health foods
George Underwood / PharmaTimes
- 2 min
Top three therapy areas dominate pipelines
The world's top three therapy areas accounted for 68 percent of the overall pharmaceutical industry pipeline as of Q1 2016, according to business intelligence provider GBI Research. The company's Innovation Tracking Factbook 2016 states that oncology is by far the largest therapy area, with almost 7,000 products in active development, almost matching the combined size of the next two therapy areas, infectious diseases and central nervous system disorders, which each have over
by Selina McKee / PharmaTimes online
- 2 min
GSK teams up with Google on bioelectronic medicines
GlaxoSmithKline is teaming up with Google's parent company Alphabet to create a new company focused on developing bioelectronic medicines. The UK drugs giant is setting up a joint venture - Galvani Bioelectronics - with Alphabet division Verily Life Sciences to enable research, development and commercialisation of new products in this relatively new field, which involves the use of miniaturised, implantable devices to modify electrical signals that might help tackle chronic d
by Beth Snyder Bulik / FiercePharma
- 2 min
Value-based care necessitates big changes for pharma marketers, says digital pharma agency
Much has been discussed, and some dismissed, when it comes to value-based care in the pharma industry. However, no one can deny that the shift to outcomes-based healthcare is a sea change that will affect big pharma significantly. Still, exactly what does value-based care mean for pharma companies? What strategic and organizational changes will drug marketers need to make? Intouch Solutions believes the change will require major shifts in pharma drug strategy, execution and m
by Ari Altstedter and Manish Modi / Bloomberg
- 3 min
India’s Drug Approvals Near Record Despite FDA Inspection Blitz
Even as the FDA has increased scrutiny of India, it’s been approving generic drug applications from the country’s firms at a record pace. The U.S. Food and Drug Administration has become something of a bogeyman for India’s stock market. An inspection blitz on Indian drug factories that supply to the U.S. helped push the broader index of Indian health-care stocks down by as much as 20 percent earlier this year from its all-time high in 2015 after some top firms received warnin
